Cabozantinib for the treatment of non-clear cell kidney cancer
A recent study published in the European Journal of Cancer shows [...]
A type of white blood cell as a potential biomarker to predict response to TKIs and overall survival
A study investigating the prognostic and predictive value of a [...]
ESMO 2018: Axitinib for the treatment of metastatic papillary renal cell carcinoma in the first-line
The results from a phase 2 clinical trial to assess [...]
Avelumab plus axitinib combination shows promise
A clinical trial looking at the combination of avelumab plus [...]
Stereotactic body radiotherapy may improve control of localised kidney cancer
A recent study published in The Journal of Urology this month [...]
Potential biomarkers may predict response to TKIs in metastatic kidney cancer
A recent study published in Clinical Cancer Research and conducted in [...]
Axitinib for metastatic non-clear cell renal cell carcinoma
Results from a phase 2 clinical trial of axitinib (Inlyta) [...]
Axitinib plus pembrolizumab combination shows promise for advanced kidney cancer
Data from a recent phase 1b study has shown that [...]
New first-line treatment option for advanced kidney cancer available on the NHS
Today, the National Institute for Health and Care Excellence (NICE) have recommended tivozanib (Fotivda) [...]
